欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - drugi antianemic priprave - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastična sredstva - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

lupin europe gmbh - mexiletine hydrochloride - myotonic motnje - srčna terapija - namuscla je primerna za simptomatsko zdravljenje myotonia pri odraslih bolnikih z ne-dystrophic myotonic motnje.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cepiva - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

斯洛文尼亚 - 斯洛文尼亚文 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

raztopina za infundiranje - karboplatin

斯洛文尼亚 - 斯洛文尼亚文 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bms Češka - paklitaksel - koncentrat za raztopino za infundiranje - paklitaksel 6 mg / 1 ml - paklitaksel

斯洛文尼亚 - 斯洛文尼亚文 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bristol-myers squibb pharma eeig - entekavir - peroralna raztopina - entekavir 0,05 mg / 1 ml - entekavir

斯洛文尼亚 - 斯洛文尼亚文 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bristol-myers squibb pharma eeig - nivolumab - koncentrat za raztopino za infundiranje - nivolumab 10 mg / 1 ml - nivolumab

斯洛文尼亚 - 斯洛文尼亚文 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bristol-myers squibb pharma eeig - raztopina za injiciranje - aztreonam

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - efavirenz - okužbe z virusom hiv - antivirusi za sistemsko uporabo - zdravilo sustiva je indicirano za protivirusno kombinirano zdravljenje odraslih, mladostnikov in otrok, starih tri ali več let, z virusom hiv-1 (virus hiv-1). sustiva ni bilo ustrezno preučevali pri bolnikih z napredovalim hiv bolezni, in sicer pri bolnikih s cd4 šteje < 50 celic/mm3, ali okvari protease-serotonina (pi), ki vsebujejo regimens. Čeprav navzkrižno odpornost efavirenz s pis ni bil dokumentiran, je zdaj na voljo dovolj podatkov o učinkovitosti poznejšo uporabo pi-temelji kombinacija terapije po okvari regimens, ki vsebujejo sustiva.